Our top pick for
Novanta Inc is a scientific & technical instruments business based in the US. Novanta shares (NOVT) are listed on the NASDAQ and all prices are listed in US Dollars. Novanta employs 2,200 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$161.51|
|52-week range||$106.95 - $168.73|
|50-day moving average||$155.70|
|200-day moving average||$141.23|
|Wall St. target price||$145.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$1.23|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-08)||0.05%|
|1 month (2021-09-17)||4.94%|
|3 months (2021-07-16)||21.58%|
|6 months (2021-04-16)||19.05%|
|1 year (2020-10-16)||40.46%|
|2 years (2019-10-17)||90.21%|
|3 years (2018-10-17)||140.09%|
|5 years (2016-10-17)||812.49%|
Valuing Novanta stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Novanta's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Novanta's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 131x. In other words, Novanta shares trade at around 131x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Novanta's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.11. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Novanta's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Novanta's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $106.5 million.
The EBITDA is a measure of a Novanta's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$620.5 million|
|Operating margin TTM||10.84%|
|Gross profit TTM||$244.7 million|
|Return on assets TTM||4.84%|
|Return on equity TTM||9.49%|
|Market capitalisation||$5.7 billion|
TTM: trailing 12 months
There are currently 659,888 Novanta shares held short by investors – that's known as Novanta's "short interest". This figure is 3.4% up from 637,963 last month.
There are a few different ways that this level of interest in shorting Novanta shares can be evaluated.
Novanta's "short interest ratio" (SIR) is the quantity of Novanta shares currently shorted divided by the average quantity of Novanta shares traded daily (recently around 132242.08416834). Novanta's SIR currently stands at 4.99. In other words for every 100,000 Novanta shares traded daily on the market, roughly 4990 shares are currently held short.
However Novanta's short interest can also be evaluated against the total number of Novanta shares, or, against the total number of tradable Novanta shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Novanta's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Novanta shares in existence, roughly 20 shares are currently held short) or 0.0191% of the tradable shares (for every 100,000 tradable Novanta shares, roughly 19 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Novanta.
Find out more about how you can short Novanta stock.
We're not expecting Novanta to pay a dividend over the next 12 months.
Novanta's shares were split on a 1:3 basis on 28 December 2010. So if you had owned 3 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Novanta shares – just the quantity. However, indirectly, the new 200% higher share price could have impacted the market appetite for Novanta shares which in turn could have impacted Novanta's share price.
Over the last 12 months, Novanta's shares have ranged in value from as little as $106.95 up to $168.73. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Novanta's is 0.9788. This would suggest that Novanta's shares are less volatile than average (for this exchange).
Novanta Inc. , together with its subsidiaries, designs, manufactures, markets, and sells photonics, vision, and precision motion components and sub-systems to original equipment manufacturers in the medical and industrial markets worldwide. Its Photonics segment offers photonics-based solutions, including laser scanning and beam delivery, CO2 laser, solid state laser, ultrafast laser, and optical light engine products for photonics-based applications, such as industrial processing, metrology, medical and life science imaging, DNA sequencing, and medical laser procedures. The company's Vision segment provides a range of medical grade technologies, including medical insufflators, pumps, and related disposables; visualization solutions; wireless, recorder, and video integration technologies for operating room integrations; optical data collection and machine vision technologies; radio frequency identification technologies; thermal chart recorders; spectrometry technologies; and embedded touch screen solutions. Its Precision Motion segment offers optical and inductive encoders, precision motors, motion control sub-assemblies, servo drives, air bearings, and air bearing spindles. The company sells its products through its direct sales force, resellers, distributors, and system integrators under the Cambridge Technology, Synrad, Laser Quantum, ARGES, WOM, NDS, NDSsi, Med X Change, Reach Technology, JADAK, ThingMagic, Photo Research, Celera Motion, MicroE, Zettlex, Applimotion, Ingenia, and Westwind brands. The company was formerly known as GSI Group, Inc.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.